Scancell (LON:SCLP) Shares Down 5.2% – Here’s Why

Scancell Holdings plc (LON:SCLP) fell 5.2% during mid-day trading on Wednesday . The company traded as low as GBX 10 ($0.13) and last traded at GBX 10.90 ($0.15). 2,669,612 shares traded hands during mid-day trading, an increase of 172% from the average session volume of 980,022 shares. The stock had previously closed at GBX 11.50 ($0.15).

Scancell Stock Performance

The firm has a 50 day moving average of GBX 8.93 and a 200-day moving average of GBX 10.68. The company has a market cap of £110.34 million, a P/E ratio of -16.33 and a beta of 0.35. The company has a quick ratio of 13.01, a current ratio of 3.42 and a debt-to-equity ratio of -566.79.

Scancell (LON:SCLP) last posted its quarterly earnings results on Thursday, January 30th. The company reported GBX (1.35) (($0.02)) earnings per share (EPS) for the quarter. As a group, sell-side analysts anticipate that Scancell Holdings plc will post -2.5361112 EPS for the current fiscal year.

About Scancell

Scancell (LSE:SCLP) is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers.

Scancell has developed a pipeline of ‘off-the-shelf’ vaccines to induce immune responses and highly tumour specific monoclonal antibodies to redirect immune cells or drugs.